Soltis Investment Advisors’s Gilead Sciences GILD Stock Holding History

Soltis Investment Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$629K	Sell	4,981 -48	-1%	-$6.32K	0.04%	319
2026 Q1	$701K	Buy	5,029 +252	+5%	+$35.3K	0.04%	274
2025 Q4	$586K	Buy	4,777 +467	+11%	+$56.8K	0.04%	301
2025 Q3	$478K	Buy	4,310 +710	+20%	+$80.7K	0.03%	305
2025 Q2	$399K	Sell	3,600 -2,113	-37%	-$225K	0.03%	281
2025 Q1	$640K	Buy	5,713 +3,097	+118%	+$320K	0.06%	208
2024 Q4	$242K	Buy	+2,616	New	+$236K	0.02%	324
2023 Q4	–	Sell	-4,982	Closed	-$373K	–	292
2023 Q3	$373K	Buy	+4,982	New	+$383K	0.05%	198

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Soltis Investment Advisors's GILD Position: Q2 2026 in Review

Soltis Investment Advisors reduced its Gilead Sciences (GILD) stake by 0.95% in Q2 2026, selling an estimated $6.32K and leaving 4,981 shares worth $629K. The position accounts for 0.04% of the portfolio, ranked #319.

Soltis Investment Advisors first reported a position in GILD in Q3 2023 and has held it in 8 quarters since. The position peaked at $701K in Q1 2026. 2,292 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Soltis Investment Advisors held 4,981 shares of Gilead Sciences worth $629K as of Q2 2026.
Soltis Investment Advisors sold 48 Gilead Sciences shares in Q2 2026, an estimated $6.32K.
Gilead Sciences made up 0.04% of Soltis Investment Advisors's portfolio in Q2 2026, its #319 holding.
Soltis Investment Advisors first reported a position in Gilead Sciences in Q3 2023 and has held it in 8 quarters since.
Soltis Investment Advisors's Gilead Sciences position peaked at $701K in Q1 2026.
2,292 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Soltis Investment Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.